Reveals that EBNA2 variants influence treatment response in multiple sclerosis, suggesting personalized therapy options.
Here, we found that infection with MS-associated EBNA2 variants might be involved in the clinical response to peg-IFN therapy. The predictive model developed, which integrates immunological and viral parameters, may help clinicians in a finer selection of first-line therapies tailored to patient profiles, supporting personalized medicine approaches.
No takes yet. Share an insight, caveat, or question.
Veroni et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: